News

Bio Products Laboratory (BPL), a leading manufacturer of plasma-derived protein therapies, with US offices in Durham, NC announced today, the kick-off of the Hereditary Factor X Deficiency in America Survey, the first of its kind focusing on patients suffering from this ultra-rare bleeding disorder.

Bio Products Laboratory (“BPL”) issues an update on its financial results and operational highlights for the six months ending 30 June 2021. BPL is a vertically integrated manufacturer of plasma-derived medicinal products headquartered in Elstree, UK. BPL consists of two divisions, BPL Plasma, based in Texas, which collects plasma from 26 centres across the US, and BPL Therapeutics in the UK, which manufactures high-quality products.

Bio Products Laboratory (“BPL”), a specialist manufacturer of plasma-derived medicinal products based in Elstree, UK, celebrates World Blood Donor Day (“WBDD”) in recognition of the critical role of donors worldwide in enhancing and saving lives.

As a growing healthcare market, India is of strategic importance to Bio Products Laboratory (BPL), the specialist manufacturer of plasma-derived medicinal products based in Elstree, UK, as the company continues to grow its global commercial presence there, and represents a business opportunity of up to £70M in the next 5 years.

Bio Products Laboratory (BPL), a leading manufacturer of plasma-derived protein therapies headquartered in Elstree, UK, today announced the signing of a collaboration agreement with Atlantic Research Group (ARG), a global contract research organization (CRO) headquartered in Charlottesville, VA.

Bio Products Laboratory (BPL), a specialist manufacturer of plasma-derived medicinal products, announces that it will be investing £23m to build a new Sterile Filling Suite at its Elstree site in the UK. From its base in Hertfordshire, BPL fractionates plasma to manufacture therapeutic products which are then supplied to patients in more than 45 countries around the world.

Bio Products Laboratory (BPL) announces today the completion of a US$370 million (£265 million) transaction for the sale of 25 of its 51 US-based plasma centres to Biomat USA Inc, a subsidiary of Grifols S.A., a global healthcare company. Approximately 730 employees will be transferring to Biomat as part of the deal.

BPL welcomes the decision made by Government to lift the ban on UK plasma being used for the manufacture of immunoglobulins. BPL is very supportive of this Government initiative which will result in plasma from UK blood donors being used to manufacture life-saving medicines, and will help the UK become self-sufficient in plasma supply.

Bio Products Laboratory (BPL), a leading manufacturer of plasma-derived protein therapies with US headquarters in Durham, North Carolina, and worldwide headquarters and manufacturing facilities in Elstree, UK, today announced the US launch of ALBUMINEX 5% (human albumin) solution for injection and ALBUMINEX 25% (human albumin) solution for injection, with supply immediately available.